MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition
Michael W.M. Kühn,
Michael J. Hadler,
Scott R. Daigle,
Richard P. Koche,
Andrei V. Krivtsov,
Edward J. Olhava,
Michael A. Caligiuri,
Gang Huang,
James E. Bradner,
Roy M. Pollock,
Scott A. Armstrong
Affiliations
Michael W.M. Kühn
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Michael J. Hadler
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Scott R. Daigle
Epizyme, Inc., Cambridge, MA, USA
Richard P. Koche
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Andrei V. Krivtsov
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Edward J. Olhava
Epizyme, Inc., Cambridge, MA, USA
Michael A. Caligiuri
The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
Gang Huang
Divisions of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
James E. Bradner
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Roy M. Pollock
Epizyme, Inc., Cambridge, MA, USA
Scott A. Armstrong
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA;Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA